Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 6;14(3):e0213210.
doi: 10.1371/journal.pone.0213210. eCollection 2019.

Exploring clinical, echocardiographic and molecular biomarkers to predict bronchopulmonary dysplasia

Maria Alvarez-Fuente  1 , Laura Moreno  2 , Paloma Lopez-Ortego  3 , Luis Arruza  4 , Alejandro Avila-Alvarez  5 , Marta Muro  6 , Enrique Gutierrez  7 , Carlos Zozaya  3 , Gema Sanchez-Helguera  8 , Dolores Elorza  3 , Andrea Martinez-Ramas  2 , Gema Villar  9 , Carlos Labrandero  10 , Lucia Martinez  9 , Teresa Casado  1 , Irene Cuadrado  9 , Maria Jesus Del Cerro  1
Affiliations

Exploring clinical, echocardiographic and molecular biomarkers to predict bronchopulmonary dysplasia

Maria Alvarez-Fuente et al. PLoS One. .

Abstract

Introduction: Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease in childhood, related to prematurity, and the most common cause of pulmonary hypertension (PH) secondary to pulmonary disease in children. Moderate and severe BPD have a worse outcome and relate more frequently with PH. The prediction of moderate or severe BPD development in extremely premature newborns is vital to implement preventive strategies. Starting with the hypothesis that molecular biomarkers were better than clinical and echocardiographic factors, this study aims to explore the ability of clinical, echocardiographic and analytical variables to predict moderate or severe BPD in a cohort of extremely preterm infants.

Patients and methods: We designed a prospective longitudinal study, in which we followed a cohort of preterm newborns (gestational age <28 weeks and weight ≤ 1250 grams). In these newborns we recorded weekly clinical and echocardiographic variables as well as blood and tracheal aspirate samples, to analyze molecular biomarkers (IL-6, IL-1, IP10, uric acid, HGF, endothelin-1, VEGF, CCL5). Variables and samples were collected since birth up to week 36 (postmenstrual age), time-point at which the diagnosis of BPD is established.

Results: We included 50 patients with a median gestational age of 26 weeks (IQR 25-27) and weight of 871 g (SD 161,0) (range 590-1200g). Three patients were excluded due to an early death. Thirty-five patients (74.5%) developed BPD (mild n = 14, moderate n = 15, severe n = 6). We performed a logistic regression in order to identify risk factors for moderate or severe BPD. We compared two predictive models, one with two variables (mechanical ventilation and inter-ventricular septum flattening), and another-one with an additional molecular biomarker (ET-1).

Conclusions: The combination of clinical and echocardiographic variables is a valuable tool for determining the risk of BPD. We find the two variable model (mechanical ventilation and echocardiographic signs of PH) more practical for clinical and research purposes. Future research on BPD prediction should be oriented to explore the potential role of ET-1.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow chart showing the patient recruitment.
Recruiting centers and recruitment periods are shown on the top row. Recruitment periods vary between hospitals due the existence of other studies recruiting the same type of patients. *One other study also aimed to recruit the same type of patients during this period. **During this two year period there were some interruptions in the recruitment due to circumstances not related with the study. ***It includes patients that did not meet inclusion criteria (3) and patients whose parents denied participation (11).
Fig 2
Fig 2
A. Levels of biomarkers in plasma of BPD (moderate/severe BPD or death) patients compared with no-BPD patients (no BPD or mild BPD) at day 7 of life. B. Comparison of the levels of biomarkers in bronchoalveolar lavage of intubated patients between the BPD and no-BPD group, at day 7 of life.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fanaroff AA, Stoll BJ, Wright LL, Carlo W, Ehrenkrantz RA, Stark AR et al. Trends in neonatal morbidity and mortality for very low birth weight infants. Am J ObstetGynecol 2007;196(14):147.e1–147.e8. - PubMed
    1. Latini G, De Felice C, Giannuzzi R, Del Vecchio A. Survival rate and prevalence of bronchopulmonary dysplasia in extremely low birth weight infants. Early Hum Dev 2013;89:S69–73. 10.1016/S0378-3782(13)70020-3 - DOI - PubMed
    1. Baraldi E, Filippone M. Chronic Lung Disease after Premature Birth. N Engl J Med 2007;357:1946–55. 10.1056/NEJMra067279 - DOI - PubMed
    1. Northway WH, Rosan RC, Porter DY. Pulmonary disease following respiratory therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967;276:357–68. 10.1056/NEJM196702162760701 - DOI - PubMed
    1. Stenmark KR, Abman SH. Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol 2005;67:623–61. 10.1146/annurev.physiol.67.040403.102229 - DOI - PubMed

Publication types

MeSH terms

Grants and funding

This study was funded by the Instituto de Salud Carlos III (Plan Estatal de I+D+i) (PI14/00219 and PI15/01100) and cofinanced by the European Development Regional Fund “A way to achieve Europe” (ERDF). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
  NODES
Association 1
twitter 2